Background
Dual antiplatelet therapy of aspirin and clopidogrel is now established as a standard of care for patients undergoing percutaneous coronary intervention (PCI) or patient with acute coronary syndrome (ACS). 1 In Percutaneous Coronary
Intervention in the Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) study, dual antiplatelet therapy (DAPT) in patients with non-ST elevation myocardial infarction (NSTEMI) lead to 31% reduction in cardiovascular death or myocardial infarction (MI). 2 Similarly, in ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT), DAPT in patients with ST elevation myocardial infarction (STEMI) was shown to reduce all cause mortality, and major cardiovascular events (MACE) including reinfarction. 3 However, despite the use of DAPT, nearly 10% patients still experience recurrent MACE. 4e7 Persistent occurrence of MACE during DAPT may be partially explained by inter-individual variability of clopidogrel response, especially in patients undergoing PCI. 8e10 One of the postulated non-modifiable factors for variability of response can be attributed to pharmacogenetics of clopidogrel metabolism.
Clopidogrel is a prodrug that requires to be converted in to active metabolites to irreversibly bind to the P2Y 12 receptor. Clopidogrel metabolism is a two steps process dependent on cytochrome P450 (CYP), with contributions from the isoenzymes like: CYP2C19, CYP3A4 or CYP3A5, CYP2C9, CYP1A2, and CYP2B6.
11e13 CYP2C19 is a key enzyme in this activation process. There are at least 9 LoF alleles in CYP2C19 gene: *2e*8 null-functioning, *9e*10 decreased functioning. The presence of carriers of the loss-of-function alleles of CYP2C19 polymorphism is associated with clopidogrel non-responsiveness in healthy people and in patients with coronary artery disease (CAD). 14e16 In addition to CYP2C19 polymorphism, variations in the gene regulating clopidogrel absorption and efflux by encoding the P-glycoprotein a multi drug resistant-1 efflux transporter (called ABCB1), 17 might also affect the rate of clinical events during treatment. According to ACC/AHA guidelines, current evidence base is insufficient to recommend either routine genetic or platelet function testing at the present time. There is no information that routine testing improves outcome in large sub-groups of patients and hence is not currently recommended. 18 Potentially relevant studies identified and screened for retrieval (n = Individual studies evaluating role of CYP2C19*2 polymorphism and ABCB1-C3435T polymorphism have yielded mix results. Therefore we performed pooled analysis of prospective studies comparing clinical outcomes in patients with CYP2C19*2 and ABCB1 polymorphism on clopidogrel therapy to evaluate association and role of clinical testing for these polymorphisms in CAD patients on clopidogrel.
Methods
We performed this review in accordance with the Quality of Reporting of Meta-analysis (QUOROM) statement and the Consolidated Standards of Reporting Trials (CONSORT) Group recommendations. 19 A protocol was prospectively developed, detailing the objectives, criteria for study selection and approach to assessing the study quality, primary outcome and methodology.
Literature search
We searched the National Library 
Study selection
Two independent authors reviewed all titles and abstracts from the results of our computerized search. We also went into the related links of all relevant articles. In addition to our computerized search, we manually reviewed the reference list of all retrieved articles to complete our search. Study selection process is outlined in Fig. 1 .
Inclusion criteria
We included in our analysis the results of randomized clinical trials or post hoc analysis of randomized control trial that compared clinical outcomes of patients with and without CYP2C19*2 and ABCB1 polymorphism in CAD patients on clopidogrel treatment. i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1 e3 5 2
All studies had to meet all the following criteria to be included in the analysis:
1. Randomized controlled trial or post hoc analysis of randomized controlled trials. 2. Include patients with coronary artery diseases mainly undergoing PCI. 3. Compare CYP2C19*2 carrier (variant) versus non-carrier (normal) and ABCB1 polymorphism (CT/TT) versus normal (CC). 4. Report at least one of the outcomes: MACE, CV death, ST, MI, stroke and major bleeding.
Exclusion criteria
Studies that did not meet the above criteria were excluded.
Data abstraction
After identifying all relevant articles, we extracted characteristics of the study like (author, year, design, duration, sample size, patient population, and genotype characteristics) and outcomes like (MACE, CV death, MI, ST, stroke, major bleeding complications and follow-up percentage). Two reviewers independently extracted data and assessed outcomes. The inter-rater agreement was 90%, and disagreements were resolved by consensus.
Quality assessment
All the trials reported adequate concealment of the randomized treatment sequence. In all studies, follow-up was more than 90% complete.
Statistical analysis
Combined relative risks (RR) across all the studies with 95% confidence intervals (CI) were computed for each endpoint by using the Comprehensive Meta-Analysis software package (version CM 2.2, Biostat, Englewood, NJ). Heterogeneity of the studies was assessed for each endpoint ( i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1 e3 5 2 studies that were heterogeneous for an endpoint were analyzed by the random effect model. A two-sided alpha error of <0.05 was considered to be statistically significant. The inverse variance method was used for study weighting. Potential publication biases were assessed by the funnel plot method and Egers test. Sensitivity, specificity, and the positive and negative predictive values of genetic testing were computed for each endpoint.
Results

Literature search for CYP2C19*2 polymorphism
A total of 107 articles were identified of which 40 were potentially relevant studies and screened for retrieval. After title and abstract evaluation, 19 studies were excluded and 21 studies were retrieved for a more detailed screening. Out of these 21 studies 7 studies were excluded and fourteen trials were included for final analysis [ Fig. 1 
Endpoints
All fourteen studies included in meta-analysis had MACE as a primary endpoint. Out of fourteen, six studies 28, 30, 33, 34, 38, 39 included in the meta-analysis had stent thrombosis (ST) as 
an endpoint, while thee studies evaluated major bleeding 28, 29, 34 and stroke 28, 38, 40 as an endpoints. Outcomes for all studies included in our analysis are given in Table 1 .
Heterogeneity testing
Results of heterogeneity testing for both CYP2C19*2 and ABCB1 polymorphisms are shown in Table 2 . For heterogeneous outcomes random effect model and for homogenous outcomes fixed effect model was used. Publication bias analysis revealed no evidence of bias except for MI and ST (Table 2 ).
Clinical outcomes of CYP2C19*2 polymorphism
The trials included in this meta-analysis consisted of a total of 19,601 patients (CYP2C19*2 carrier group, n ¼ 5540; non-carrier group, n ¼ 14,061). 
Myocardial infarction (MI)
n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1 e3 5
There was a significant increase of MI events in carrier group in ACS patients [RR: 1.98 
Test parameters of CYP2C19*2 polymorphism
Test parameter analysis was done using 2 Â 2 table. Genetic assay for CYP2C19*2 polymorphism was found to have sensitivity of (28e58%), specificity of (71e73%), negative predictive value of (92e99%) and positive predictive value of (3e10%) for various outcomes studied in this meta-analysis. Test parameters for individual outcomes are given in Table 3 .
Clinical outcomes of ABCB1 polymorphism
The trials included in this meta-analysis consisted of a total of 8758 patients (non-carrier group, n ¼ 6384; carrier group, n ¼ 2374). The results of ABCB1-C3435T polymorphism summarized in Fig. 5 i 
Discussion
The present meta-analysis included nearly 19,600 patients from 14 prospective clinical trials conducted through May, i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1 e3 5 2
Relative Risk of MI in ACS: CYP2C19 Normals vs Variants
2011. This pooled analysis is different from previous metaanalysis, 42e45 as we assessed not only the association but also the CYP2C19*2 genetic testing parameters for individual outcomes. We also analyzed the role of ABCB1 polymorphism in clopidogrel non-responsiveness and included separate subanalysis of three different patient populations to identify the population at risk. Results of our analysis show that CYP2C19*2 polymorphism is associated with significantly increased relative risk of MACE (1.28 fold), MI (1.3 fold), CVS death (3 fold), ST (2.4 fold) and stroke (4 fold) without any decrease or increase in the incidence of bleeding events. Moreover, stable patients undergoing elective PCI also have significantly increased risk for MACE (1.3 fold) with CYP2C19*2 polymorphism carrier state. Additionally, it shows ABCB1 polymorphism is not associated with increased incidence of MACE or ST.
Majority of stent thrombosis occur early (<30 days) and according to previous reports incidences are approximately 1% that causes serious consequences like MI, CVS deaths and strokes. 46 According to our analysis, compared to normal genotype, CYP2C19*2 polymorphism was associated with higher incidence of stent thrombosis, MI, CVS deaths and strokes. Overall, we found higher risk of ST (2.4 fold) as compared to MACE (1.28 fold). This could be due to the fact that MACE was reported in 14 studies while ST was reported by only six studies with wide confidence intervals. Based on our data, CYP2C19*2 polymorphism genotyping has around 10% positive predictive value for almost each adverse outcomes (MI, MACE, CVS deaths etc.) which suggest that genotyping has no predictive value to detect studied outcomes. On the other hand, normal CYP2C19 had a very high (90e100%) negative predictive value for almost each adverse outcome. Thus, patients without CYP2C19*2 i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1 e3 5 2 polymorphism are at very low risk of having an adverse event while in case of polymorphisms, the negative outcome does not seem to be predictable. This is true despite that the overall RR values indicate higher risks in this patient group. Thus, it is reasonable to think that there are other (unknown?) factors that play the major role in the negative outcomes in CYP2C19*2 polymorphism group of patients. This finding indicates the potential role genotype testing may play in evaluating genetically non-modifiable factors responsible for clopidogrel non-responsiveness in patient with recurrent ischemic events. However, due to the poor sensitivity and low positive predictive value, routine genetic testing cannot be recommended at present. Our data also shows that ABCB1 polymorphism has no clinical role in clopidogrel non-responsiveness in patient undergoing PCI or patients with ACS. Although, this data only compares, the 3435C / T heterozygous/homozygous variant (includes CT/TT) to normal (CC) while data comparing homozygous variant (TT) to normal (CC) is not known and is a subject to be evaluated in future study.
Subgroup analysis of stable CAD patients undergoing elective PCI shows higher incidence of MACE (1.3 fold) in variant group compared with normal group, which contradicts the conclusion drawn from CHARISMA genomic substudy that indicated no association with ischemic outcomes in CYP2C19*2 heterozygotes. 35 As previously mentioned, high on treatment platelet reactivity (HTPR) is the pathophysiologic phenomenon behind the development of recurrent ischemic events in ACS patients or patients undergoing PCI. 47 Apart from pharmacogenetic polymorphism, other factors also contributes to HTPR are non-compliance, underdosing, drugedrug interactions, co-morbidities (diabetes mellitus, abnormal renal function, hyperlipidemia, obesity) active smoking, clinical presentation, and procedural complexities. 7 According to initial data published in GRAV-ITAS trial (Price et al) shows that even after adjusting clopidogrel therapy (maintenance dose 150 mg), based on persistent HTPR assessed by platelet function test, did not result in change in clinical outcomes and persistent HTPR was attributed to non-modifiable risk factors like clinical presentation, procedural characteristics and genetic polymorphism. 48 Therefore, combining platelet function testing to identify the HTPR followed by genotyping to identify CYP2C19*2 polymorphism may give us guidance to use alternate anti-platelets like prasugrel 49 or ticagrelor. 33 Overall, the prevalence of laboratory-defined clopidogrel non-responsiveness has been estimated at 21e26%. 50 Clinical implications to clopidogrel non-responsiveness of CYP2C19*2 polymorphism are obvious since significant number of population has at least one loss-of-function CYP2C19 allele: z30e50% of Asians, 11e16% of Caucasians, and 14e25% of African-Americans. 51 Recently, FDA issued black box warning regarding use of clopidogrel in poor metabolizers but recommended against routine genotyping in patients on clopidogrel therapy. 52 Our meta-analysis indicates that CYP2C19*2 polymorphism results in significantly increased risk of cardiovascular events like MI, ST and CV deaths. Therefore it is imperative to have clinical trial designed to evaluate clinical benefit of personalizing antiplatelet therapy based on genotyping and platelet function test.
As with any meta-analysis, one of the limitations of our study is the difference in the definitions of the endpoints in the component trials, such as the definition of MACE, MI and CV death was different in various studies. Also, there was also heterogeneity in the study population, follows up duration, clopidogrel therapy protocol. Similarly, baseline characteristics between the two groups cannot be compared completely in most meta-analyses because of differences in the study protocols across the component trials. Also, there is a potential for publication bias but the trials in our analysis had different results and it should reduce this potential risk. Moreover, publication bias analysis was negative for all outcomes except for MI and ST indicating robustness of our results.
Conclusion
In CAD patients on clopidogrel therapy, CYP2C19*2 polymorphism is associated with significantly increased adverse cardiovascular events. However, due to the low positive predictive value, routine genetic testing cannot be recommended at present and should not be performed.
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